Bone marrow transplantationHumansCyclophosphamideGraft vs Host DiseaseMaleFemale
Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity.
Ioanna Lazana, Konstantinos Gkirkas, Ioannis Konstantellos, Chrisovalanto Chatzidimitriou, Aggeliki Karagiannidou, Georgia Gkolfinopoulou, Maria Stamouli, Spiros Chondropoulos, Panagiotis Tsirigotis
Published: 202610.1038/s41409-025-02736-6
Abstract
Post-transplant cyclophosphamide (PTCy) has been explored as GvHD prophylaxis in matched related and unrelated donor transplants with encouraging outcomes, although at the cost of increased toxicity. A prospective, single-center study was conducted t…
Preview only. Read the full abstract at the source